BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26403403)

  • 1. PAPILLARY THYROID CANCER IS CHARACTERIZED BY ALTERED EXPRESSION OF GENES INVOLVED IN THE SUMOYLATION PROCESS.
    Tuccilli C; Baldini E; Sorrenti S; Di Gioia C; Bosco D; Ascoli V; Mian C; Barollo S; Rendina R; Coccaro C; Pepe M; Catania A; Bononi M; Tartaglia F; De Antoni E; D'Armiento M; Ulisse S
    J Biol Regul Homeost Agents; 2015; 29(3):655-62. PubMed ID: 26403403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Falvo L; De Vito C; Catania A; Tartaglia F; Mocini R; Coccaro C; Alessandrini S; Barollo S; Mian C; Antonelli A; De Antoni E; D'Armiento M; Ulisse S
    PLoS One; 2015; 10(3):e0121514. PubMed ID: 25807528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulated expression of VHL mRNA variants in papillary thyroid cancer.
    Baldini E; Tuccilli C; Arlot-Bonnemains Y; Chesnel F; Sorrenti S; De Vito C; Catania A; D'Armiento E; Antonelli A; Fallahi P; Watutantrige-Fernando S; Tartaglia F; Barollo S; Mian C; Bononi M; Arceri S; Mascagni D; Vergine M; Pironi D; Monti M; Filippini A; Ulisse S
    Mol Cell Endocrinol; 2017 Mar; 443():121-127. PubMed ID: 28089820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
    Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
    J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
    Jia M; Guo Y; Lu X
    Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Differential Expression Patterns of Sumoylation Enzymes E1, E2 and E3 in Ocular Cell Lines.
    Nie Q; Xie J; Gong X; Luo Z; Wang L; Liu F; Xiang JW; Xiao Y; Fu JL; Liu Y; Chen Z; Yang L; Chen H; Gan Y; Li DW
    Curr Mol Med; 2018; 18(8):509-515. PubMed ID: 30636610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressed Krüppel‑like factor 17 expression induces tumor proliferation, metastasis and a poor prognosis in papillary thyroid carcinoma.
    Ye WC; Gao L; Huang J; Fang XM; Xie G
    Mol Med Rep; 2014 Oct; 10(4):2087-92. PubMed ID: 25109837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
    Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
    Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and clinical significance of STIP1 in papillary thyroid carcinoma.
    Yuan MH; Zhou RS; She B; Xu HF; Wang JY; Wei LX
    Tumour Biol; 2014 Mar; 35(3):2391-5. PubMed ID: 24163084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma.
    Sun M; Fang S; Li W; Li C; Wang L; Wang F; Wang Y
    Cancer Biomark; 2015; 15(1):33-40. PubMed ID: 25524940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
    Hussain AR; Bu R; Ahmed M; Jehan Z; Beg S; Al-Sobhi S; Al-Dayel F; Siraj AK; Uddin S; Al-Kuraya KS
    J Clin Endocrinol Metab; 2015 Jul; 100(7):E974-85. PubMed ID: 25974735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotinidase is a novel marker for papillary thyroid cancer aggressiveness.
    So AK; Kaur J; Kak I; Assi J; MacMillan C; Ralhan R; Walfish PG
    PLoS One; 2012; 7(7):e40956. PubMed ID: 22911723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
    Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
    Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
    Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
    Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma.
    Zhao Y; Liu X; Zhong L; He M; Chen S; Wang T; Ma S
    Int J Mol Med; 2015 Oct; 36(4):1097-103. PubMed ID: 26252081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
    Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
    J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.
    Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
    Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
    Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
    Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
    Jiang XL; Zhang H; Chen YL; Peng L
    Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.